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Edited by Beat ImhofAbstract It is generally observed that countries with heavy
infectious burden show lower cancer incidence as compared to
more aﬄuent nations. With the emerging paradigm on microbial
heat shock proteins (hsps) as molecular link between infections
and autoimmune diseases, we posit a new hypothesis, the ‘‘mimo-
tope-hormesis’’, on the immunologic impact of infections on re-
gional cancer prevention. According to this, assaults of
infection during early adulthood could fortify the immune system
to evoke more potent defenses against late-onset diseases, such
as cancer, via autoimmunity. Interestingly, both experimental
and clinical data support the beneﬁcial role of autoimmunity in
long-term cancer survivors. We illustrate this by a comprehensive
in silico mimotope (epitope mimicry) analysis of human infec-
tious pathogens against mortalin (mthsp70/PB74/GRP75), a
type of hsp70 protein involved in the control of cell proliferation,
immortalization and tumorigenesis.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Although speciﬁc infectious agents (e.g., HPV in cervical
cancer, Helicobacter pylori in gastric cancer, Schistosoma
japonicum with bladder cancer, etc.) that target cellular onco-
genes and tumor suppressors, induce chronic inﬂammation
and result in production of reactive oxygen species have been
associated with malignancies [1,2], many regions of the world,
particularly the developing countries, in spite of having high
infectious disease burden appear to show an inverse trend in
terms of cancer incidence [3–5]. The reason for this is not yet
well understood and will likely rely on individual genetic
make-up, cancer type, infection history and a host of environ-
mental factors.
A provocative and legitimate hypothesis that has stemmed
from the non-linearity between dose and response (for exam-
ple, low-dose stimulation and high-dose inhibition) in biologi-*Corresponding author. Fax: +81 29 861 2900.
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evidence in the recent past is the concept of hormesis. It is
broadly deﬁned as a beneﬁcial or positive eﬀect of low doses
of an otherwise harmful agent or stressor. The most widely
known is radiation hormesis that is commonly implicated in
the observed decreased cancer risk from low-dose irradiation.
Anti-aging and life-prolonging eﬀects of a wide variety of the
so-called stressors, such as irradiation, caloric restriction, heat
shock, pro-oxidants, aldehydes and hypergravity, have been
dissected from cellular to organismic levels [6–12]. Corre-
spondingly, we put forward here a hypothesis on mimotope-
hormesis that may provide a rational and integrative molecular
link to the inverse trend of infectious disease burden and
cancer.2. Hormesis hypothesis and tumor vaccinology
The thrust of mimotope-hormesis, in part, relies on the initi-
ation and long-term survival of a T and B cell pool capable of
mounting protective immune responses. In early adulthood,
individuals may be challenged by an enormous variety of
pathogens, which activate high-aﬃnity repertoires that may
be cross-reactive to tumor antigens [13]. From another perspec-
tive, ‘‘beneﬁcial’’ autoimmunity may particularly be exploited
as an eﬀective preventive or prophylactic measure for a large
variety of old age cancers. This is in contrast with the proposed
immunotherapies that are expensive and require repeated
administration for longer durations. Hence, identiﬁcation of
mimotopes (epitope mimetics) by combinatorial epitope dis-
covery with peptide libraries, or by recently developed in silico
strategies, as demonstrated in this study and their use as alter-
natives to natural antigens that are not readily available for
serological testing and vaccine development, are now a most
challenging avenue in tumor immunology research [13–18].
As vaccines, for example, ﬁve candidate mimotopes of Her-
2/neu, a gene upregulated in most breast cancers, have been
identiﬁed by phage display using the humanized monoclonal
antibody Herceptin. The strong immunological response to
these peptides makes them suitable candidates for formulation
of a breast cancer vaccine [17]. In another study, mimotopes of
a shared tumor-associated T cell epitope in cutaneous
lymphoma were tested for their capacities to induce clinicalblished by Elsevier B.V. All rights reserved.
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reactive peptides were derived using a combinatorial peptide li-
brary without any prior knowledge of the corresponding natu-
ral tumor-associated antigen. Vaccination with these
mimotopes together with helper T cell-inducing antigens led
to complete tumor remission in the two patients tested. After
each booster vaccination, enhanced frequencies of mimotope-
speciﬁc CD8+ T cells were detected in the peripheral blood
of the patients, and the CTL proved to be cytotoxic and
tumoricidal when tested in vitro. These data provided the ﬁrst
indication of clinical eﬃcacy of mimotopes in cancer patients
[16]. Notably, this phenomenon of epitope mimicry (mimot-
opy) has been proposed as an initiator of tumor-directed
auto-immunity observed among long-time survivors [19].
Mimotopes for heat shock proteins have been shown to trig-
ger beneﬁcial autoimmune responses [20,21]. This is consistent
with the observation that average mortality rate of cancer pa-
tients with multiple sclerosis, an autoimmune attack against
‘‘self’’ hsp70, is signiﬁcantly lower than that of ordinary cancer
patients [22]. In this paper, we associate mimotopy as an
important component of an immunologic hormetic phenome-
non. We demonstrate this by showing by an in silico epitope
analysis of mortalin and hsps from known human pathogens.3. Hsps as potential therapeutics and trigger factors of
autoimmune diseases
Heat shock proteins are ancient families of chaperones for
the folding/unfolding, degradation/stabilization, translocation
of proteins during various stresses, such as heat shock, ER-
stress, glucose deprivation, etc. Originally recognized for their
role in resistance to stress, they have received a lot of attention
from immunologists for their ability to stimulate the adaptive
and innate immune system. Tumor cells subjected to a non-
lethal heat shock stress are unable to form tumors in syngenic
mice. This is attributed to the enhancement of T-cell-mediated
response with the expression of the inducible hsp70 that func-
tions in antigen processing and presentation by MHC I [23].
Furthermore, immunogenicity of hsps is believed to be en-
hanced from the antigenic peptides with which they associate
with and, hence, the use of HSP-peptide complexes has been
proposed as tumor vaccines [24]. Hsp70 puriﬁed from malig-
nant and virally infected cells could transfer and deliver anti-
genic peptides to APCs to elicit peptide-speciﬁc immunity
[25]. The conserved nature of hsp70 proteins and their inherent
immunogenicity, alone or in tandem with another protein,
prompted that they may provide the link between infection
and autoimmunity by acting as autoantigens with which,
molecular mimicry could play a dominant role [24–27].
As auto-antigens on the other hand, reactivity to heat shock
proteins may explain associations between infectious agents
and autoimmunity that include b-hemolytic streptococci and
rheumatic fever; Trypanosoma cruzi and Chagas disease;
Borellia burgdorﬁi and Lyme arthritis; Rubella and type 1 dia-
betes [28–30]. Certain strains of rats, for example, developed
severe polyarthritis that resembled rheumatoid arthritis in hu-
mans after immunization with heat-killed Mycobacterium
tuberculosis and its hsp60 epitopes [31]. Correlations of anti-
hsp60 autoantibodies and disease severity have been demon-
strated for patients with atherosclerosis [32], psoriasis [33],
cystic ﬁbrosis [34], Kawasaki disease [35] and Behcets dieases[36]. On one end, insulin-dependent diabetes mellitus in NOD
mice was inhibited by immunization with a cross-reactive epi-
tope of hsp60, termed as p277. This epitope activated a pool of
CD4+ T-cell clones underscoring the potential of hsps for pep-
tide therapy while highlighting the complexity of immune re-
sponse to hsps [37]. For hsp70, reactive T cells and
antibodies were detected in serum and cerebrospinal ﬂuid of
multiple sclerosis patients [38], while paradoxically, a bolus
of recombinant hsp70 attenuated some experimental autoim-
mune diseases [39]. Whilst, other studies failed to provide evi-
dence that the titer levels exceeded those found in normal
subjects [40]. A robust phage display strategy was able to
identify another hsp70 member, GRP78, as major tumor-
associated antigen in serum of prostate cancer patients [41].
Mortalin/PBP74/GRP75 (Accession No. P38646) is a unique
member of the hsp70 family and is associated with cell prolif-
eration, tumorigenesis and immortalization [42–44]. It also
functions in antigen processing, stress response, cell prolifera-
tion, diﬀerentiation and tumorigenesis [43–47]. Mortalin is
both overexpressed and diﬀerentially localized (pancytoplas-
mic in normal to perinuclear in immortal cells) in all human
tumor-derived and in vitro immortalized cells analyzed so far
[48,49]. In a comparative proteome proﬁle of the cell surface
of tumors, mortalin is also found to be one of the more abun-
dant residents along with some other chaperones and known
cell surface markers, e.g., immunoglobulin and laminin recep-
tors [50]. These evidences (overexpression, altered localization
and protein clients) are indicators for mortalins potential neo-
immunogenicity during carcinogenesis. While it shares 70–80%
homology with other known hsp70s from microbial and para-
sitic infections, we deem mortalin as a highly attractive candi-
date in exploring the phenomenon of epitope mimicry
(mimotopy) by infectious agents and in formulating a model
on how such molecular events could possibly translate to tu-
mor regression, or cancer prevention at a population level.4. In silico identiﬁcation of tumor-associated hsp70 mimotopes
We identiﬁed epitopes using an HLA-DR ligand prediction
software TEPITOPE obtained from Dr. Hammer and co-
workers [51,52]. Peptide strings strongly binding to at least
three of the eight HLA-DR alleles (DRB1*0101, DRB1
*0301, DRB1*0401, DRB1*0701, DRB1*0801, DRB1*1101,
DRB1*1501 and DRB5*0101) were selected as promiscuous
epitopes based on the reported criteria from previous work
on TEPITOPE-based vaccines [53,54]. These MHC alleles ac-
count for more than 90% of the HLA class II isotypes on anti-
gen presenting cells [55]. Prediction threshold was set at 1%
such that our identiﬁed epitope would belong to the top 1%
best binders based on a pool of 8000 peptide frames from a
randomized library of peptide sequences [56].
We also obtained hsp70 protein sequences of 76 bacteria, 29
mycoses and 11 parasites of medical relevance [57] available
from the NCBI (http://www.ncbi.nlm.nih.gov/) and EXPASY
(http://us.expasy.org/) websites and aligned the sequences with
Clustal W to identify regions possessing 100% homology with
mortalin epitopes. Such homologous sequences were desig-
nated as mimotopes. Five immunodominant clusters of mort-
alin were identiﬁed and of these, VLLLDVTPLS and
LGQFLIGPPAPR appeared promiscuous. Out of 116 protein
sequences examined, only 14 pathogen-derived hsp70s showed
Table 1
Mortalin mimotopes from human pathogens
Cross-reactivity, in this case, corresponds to pathogens proteins sharing 100% homologies with mortalin epitopes. Quantitative evaluation of
promiscuity of the two mimotopes is shown at the right. Bars indicate the threshold setting at which peptide is predicted as ligand for each listed
HLA-DR allele. Peptides displaying aﬃnity for two out of the ﬁve designated HLA-DRs (see Part 2) at 1% are designated as highly promiscuous
[54–62].
588 C.C. Deocaris et al. / FEBS Letters 579 (2005) 586–590100% homology to mortalin epitopes (Table 1) with
VLLLDVTPLS appearing to be most cross-reactive. It is also
observed that number of non-promiscuous epitopes, or pep-
tides that do not bind to a wide range of human MHCs, do
not fall in the highly conserved regions (data not shown).
Interestingly, infectious agents that bear mortalin mimo-
topes are highly prevalent in developing and agricultural re-
gions and are often associated with non-hygienic
environments and poor food manufacturing standards, like
Escherichia coli, Salmonella and Shigella. Cross-reactivity be-
tween cancer cells, i.e., guinea pig line 10 hepatocarcinoma cell,
and chronic infectious agents has been reported in Brucella
abortus as early as 1976 [58]. Leptospirosis is worldwide in dis-
tribution, but is more prevalent in regions having warmer cli-
mates and frequent ﬂoods. Caveat, associations drawn based
on the characteristics and epidemiology of the pathogens
may be crude as cancer is a highly complex disease that brings
forth interactions of individual genetic susceptibility and envi-
ronmental factors. Moreover, we do not discount the possibil-
ity that cancer diagnostic methods and tumor registries may
not be properly in place and statistics may be underestimated.5. The mimotope-hormesis model for mortalin
From an immunologic standpoint, in some clinically ad-
vanced cases, anti-tumor antibodies that are detected come
from a circulating pool of low avidity T and B cells targeted
against cryptic determinants. More often, such autoimmune
reaction may not be suﬃcient for tumor regression to happen.Two probable strategies for a ‘‘beneﬁcial’’ autoimmunity by
exogenous cross-reactive antigens may be staged: ﬁrst, epitope
mimicry can prime a second pool of precursor lymphocytes
harboring high aﬃnity towards immunodominant domains
of the tumor and this, consequently, is expected to escape
selective pressures since they pose as primordial armamentaria
against the microbial/parasitic invader [13]; second, a ‘‘double
whammy’’ may seem to happen, whereby cross-reactive anti-
bodies target a rogue cell at the very early stage of carcinogen-
esis, as exempliﬁed by mortalin, a cognate for cellular
immortalization. Thus, immunologic memory for the promis-
cuous cross-reactive determinants of mortalin may be gener-
ated within a population based on frequent re-stimulation by
subsequent onslaughts by these microbes.6. Possible rebuttal against the model
In an independent way, infection may also cause modulation
of the Th1 and Th2 balance and concurrent activation of non-
speciﬁc ‘‘innate’’ immune response that have suppressive ef-
fects on tumor growth. These have been shown from an earlier
work on anti-tumor eﬀects of lipopolysaccharide preparations
from Shigella sonnei and Bordetella pertussis [59]. Truly, as
components of the MHC II pathway, the Th1 response in-
duced by acute infections, e.g., from toxoplasma and Listeria
monocytogenes, but not the Th2 response from S. japonicum,
has been demonstrated to inhibit implanted B16 tumors in
mice [60]. Activation of macrophages with tumoricidal acitiv-
ity, though not dependent on MHC recognition, can be
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microorganism, such as mycobacteria, Listeria and Toxo-
plasma; endotoxins, soluble products from bacteria and by
the principal Th1 cytokine IFNc. Natural killer cells that can
lyse a number of tumor cells, are similarly activated by cyto-
kines IFNc, IL-2 and IL-2 during acute inﬂammatory pro-
cesses [61]. However, such innate immunity, in contrast to T
and B cells, does not confer immunologic memory and may
not impact as much during the long carcinogenesis time frames.
Included among the candidate mimotopes was a hsp70 pep-
tide from S. japonicum, a major disease agent in Africa, Egypt,
the southern parts of Europe, and Japan. Paradoxically, to-
gether with Opisthorchis and Clonorchis, it belongs to a major
genera of parasites that are known or suspected cancer risk
factors. Oncogenic characteristics of schistosoma operative
during bladder carcinogenesis have not been completely eluci-
dated. It is believed that the parasite involves the production of
excessive reactive oxygen species via inﬂammation, elevated
bladder cell proliferation, genetic instability, and interaction
with other carcinogens and co-infection with viral agents
[62]. Recently, schistosomal infection has also been shown to
inﬂuence DNA methylation in key cancer genes [63]. In the
parlance of hormesis, Schistosoma, along with other known
carcinogenic infectious agents, EBV, HPV, H. pylori among
others, cannot be categorized as ‘‘mild stress’’. Long-term hor-
metic eﬀects of any form of mimotope-associated tumor auto-
immunity, however, may exert its beneﬁts in all but the types
of tumors that are known to be targets of these microbes as
a direct result of their pathogenicity.7. Concluding remarks
Emerging evidence supports the role of hsps and their epitope
mimics (mimotopes) in priming immune responses, both in
improving host defenses and in auto-aggression. Along such
line, this article proposes novel attributes of mortalin/GRP75/
mthsp70 as an immunomodulator expounding beyond its
known chaperone functions and proposes it as a candidate can-
cer vaccine. Supported by the data on epitopes shared by mort-
alin (enriched in immortal and cancerous cells), and hsp70
cognates in human pathogens prevalent in developing countries,
we put forward a hypothesis that the phenomenon of epitope
mimicry may play a role in regional cancer prevention and ex-
plain the inverse trend in cancer and infection in developing
countries. In this way, the ‘‘mimotope hormesis hypothesis’’
provides a molecular glass-half-full view that perhaps havoc
wrought by these infections may, in a way, spare populations
of miseries of cancer in the poorer regions of the world.References
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